N-myc downstream regulated gene 1 acts as a tumor suppressor in ovarian cancer

  • Authors:
    • Bei Wang
    • Jianli Li
    • Zhanying Ye
    • Zhe Li
    • Xiaohua Wu
  • View Affiliations

  • Published online on: March 11, 2014     https://doi.org/10.3892/or.2014.3072
  • Pages: 2279-2285
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Although implicated in a number of tumor types, the role of N-myc downstream regulated gene 1 (NDRG1) in ovarian cancer (OC) is unclear. In the present study, we used short hairpin RNA (shRNA) to silence NDRG1 in the OC cell line OVCAR3 and assessed the effect of its knockdown on cell morphology, proliferation, colony formation, migration and invasion. To complement these knockdown studies, we overexpressed NDRG1 in the same cell line. We found that NDRG1 knockdown significantly enhanced OVCAR3 proliferation, migration and invasion; however, there were no apparent changes in cell morphology. We also examined the effect in vivo and found that NDRG1 depletion promoted OVCAR3 xenograft growth in nude mice. In accordance with these data, we found that NDRG1 overexpression decreased proliferation, adhesion and apoptosis, and induced G0/G1 cell cycle arrest in OVCAR3 cells; expression of p21 and p53 was also increased. In conclusion, we demonstrated that NDRG1 acts as a tumor suppressor in ovarian carcinogenesis and may be a potential therapeutic target in this disease.


Ovarian cancer (OC) arises from malignant transformation of the female ovaries. In the US in 2009, there were an estimated 21,880 newly diagnosed cases and 13,850 deaths resulting from the disease (1). The high rate of death may be attributed to late-stage diagnosis; approximately two-thirds of patients are diagnosed with stage III or IV disease (2). OC is the leading cause of death among gynecological cancers with an overall 5-year survival rate of ~19–39% (3). Unfortunately, current treatment strategies are lacking. Thus, a more comprehensive understanding of OC is required to develop additional potentialy targeted therapies that can increase the survival of those diagnosed with the disease.

A number of studies have examined the genetic alterations and signal transduction changes that occur upon initiation and progression of OC (4). Despite these findings, there is still much knowledge concerning the underlying mechanisms governing OC growth that is unknown.

In the present study, we examined a possible role of N-myc downstream regulated gene 1 (NDRG1) in OC. NDRG1 belongs to a family of genes consisting of four members which all share ~57–65% sequence identity (5). NDRG1 is predominantly cytoplasmic, and the protein is ubiquitously expressed both in normal and neoplastic tissues. Additionally, it is highly conserved among multicellular organisms (6). NDRG1 has been implicated in carcinogenesis, particularly in invasion and metastasis (7,8). However, it may play distinct roles in different types of tumor. NDRG1 has been reported to act as a tumor suppressor in a number of cancers, including breast (9), prostate (1012), pancreatic (7,8,13), cervical (14), highly metastatic colon (15) and gastric cancer (16). However, in hepatocellular carcinoma, NDRG1 may actually promote growth (17,18). The exact role of NDRG1 in OC has not been well studied. Thus, in the present study, we examined the role of NDRG1 in four OC cell lines. We both knocked down and overexpressed NDRG1 in the OC cell line OVCAR3 and found that it exhibited a growth suppressive function in this cell line. These studies provide evidence for additional, more comprehensive, analyses of NDRG1 in OC.

Materials and methods

Reagents and cell culture

Human OC cell lines HO8910, OVCAR3, SKOV3 and A2780 were obtained from the Chinese Academy of Medical Sciences. HO8910 and SKOV3 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (HyClone, Thermo Scientific, Waltham, MA, USA). OVCAR3 and A2780 cells were cultured in RPMI-1640 medium (HyClone). All medium was supplemented with 10% fetal bovine serum (FBS) (HyClone) and 1% penicillin/streptomycin. Cells were maintained in a 37°C incubator supplied with 5% CO2.

Construction of short hairpin RNA (shRNA) plasmids

shRNA directed against human NDRG1 was purchased from GenePharma Biotechnology (Shanghai, China); all sequences are listed in Table I. The shRNA effective target sequence for NDRG1 was 5′-TTCAAGAGA-3′. OVCAR3 cells were stably transfected with recombinant NDRG1-targeted shRNA plasmids or a control shRNA vector using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Stable clones were confirmed by real-time RT-PCR and western blotting. The resulting cell lines were designated as OVCAR3-shNDRG1 and OVCAR3-shNC (negative control).

Table I

Short hairpin RNA sequences designed with the GenScript siRNA target finder.

Table I

Short hairpin RNA sequences designed with the GenScript siRNA target finder.


[i] F1, F2, F3, three different RNAi sequences targeting NDRG1; control, non-targeting sequence. siRNA, short hairpin RNA; F, forward; R, reverse; NDRG1, N-myc downstream regulated gene 1.

Quantitative real-time PCR

Total RNA was extracted with TRIzol reagent (Invitrogen). A cDNA synthesis reaction (20 μl) was set up using PrimeScript RT reagent kit (Takara, Otsu, Shiga, Japan) according to the manufacturer’s instructions. Reaction conditions were as follows: 25°C for 10 min, 42°C for 30 min and 85°C for 5 min. cDNA was then amplified and detected using SYBR Premix Ex Taq™ Perfect Real-Time PCR Master Mix kit (Takara). Real-time PCR was performed as follows: stage 1, pre-denaturation at 95°C for 10 min; stage 2, 40 cycles of 95°C for 15 sec, 58°C for 20 sec and 72°C for 27 sec; dissociation, 95°C for 15 sec, 60°C for 30 sec and 95°C for 15 sec. The melting curve for each primer pair was analyzed to verify specificity of the amplified product. Gene expression levels were normalized to β-actin and relative gene expression was determined as previously described (19). Primer sequences and expected product sizes are as follows: 5′-CGCCAGCACATTGTGAATGAC-3′ (forward) and 5′-TTTGAGTTGCACTCCACCACG-3′ (reverse) for NDRG1; 5′-CATCCTCACCCTGAAGTACCC-3′ (forward) and 5′-AGCCTGGATAGCAACGTACATG-3′ (reverse) for β-actin.

Western blotting

Total cell lysates were prepared with RIPA buffer containing phenylmethylsulfonyl fluoride (PMSF; Beyotime Institute of Biotechnology, China). Equal amounts of protein were separated by SDS-PAGE (10% polyacrylamide gels) and transferred to nitrocellulose membranes. The membranes were blocked with 5% milk in Tris-buffered saline containing 0.05% (v/v) Tween-20 for 1 h at room temperature. This was followed by overnight incubation with the appropriate antibody (rabbit anti-NDRG1 monoclonal antibody, cat. no. ab32072, 1:10,000; Abcam, UK; mouse anti β-actin monoclonal antibody, cat no. 600008-1-Ig, 1:1,000; ProteinTech, USA) at 4°C. The protein signal was detected with an ECL system (Millipore) and photographed with FluorChem E image system (Cell Biosciences).

Morphological analysis of the cultured cells

NDRG1-depleted cells (OVCAR3-shNDRG1) and control cells (OVCAR3-shNC) were seeded onto chamber slides and left overnight. The next day they were fixed with 4% paraformaldehyde, stained with 1% crystal violet and examined by light microscopy.

Cell proliferation assay

A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay kit (Beyotime, China) was used. Briefly, OVCAR3 cells transfected with shRNA-NDRG1 or shRNA-NC were plated in triplicate in 96-well plates and incubated for 24 h to allow cells to attach. After 48 h, the MTT assay was performed using 20 μl of serum-free medium containing MTT (0.5 g/l) and incubating at 37°C for 4 h. Next, 150 μl DMSO was added to each well, and all plates were shaken at room temperature for 10 min. Optical density (OD) was measured at 490 nm using a spectrophotometer microplate reader. Cellular proliferation graphs were plotted. Each experiment was performed in triplicate wells and was repeated at least three times.

Colony formation assay

Briefly, OVCAR3-shNDRG1 and OVCAR3-shNC cells were plated in 6-well plates at a density of 1,000 cells/well. After 10 days of incubation in 10% FBS containing 200 μg/ml G418, the cells were fixed with 4% paraformaldehyde and stained with 1% crystal violet. Colonies were counted under a light microscope.

Cell migration and invasion assays

Invasion assays were performed using the BD BioCoat™ Matrigel chamber in 24-well plates (BD, USA). Resuspension solution (100 μl) containing 1.5×105 cells in DMEM with 1% FBS was added to the upper chamber, and 600 μl DMEM supplemented with 20% FBS was added to the bottom chamber. After a 48-h incubation at 37°C in a 5% CO2 incubator, cells in the upper well were wiped off using a cotton swab. Cells in the lower chamber were fixed, stained with H&E, and counted under a light microscope. The migration assay was performed in a similar manner except that the chambers were covered without Matrigel.

Wound healing assay

Cells from each group (OVCAR3-shNDRG1 and OVCAR3-shNC) were seeded into 6-well plates (5×105 cells/well). The confluent monolayer was starved overnight, and then a single, linear scratch was created using a 20 μl pipette tip. After wounding, the cells were washed gently with PBS to remove cell debris and placed in fresh DMEM supplemented with 0.1% FBS to block cell proliferation. Images were captured using a phase contrast microscope at ×200 magnification at 0, 24 and 48 h. The wound size was measured and analyzed using ImagineJ software. Wound closure was expressed as a percentage of the wound area at 0 h.

Xenograft experiments

Twenty nude mice (Balb/c athymic nude mice), aged 4–6 weeks (weighing ~20 g) were randomly divided into two groups. OVCAR3 cells were suspended in sterile PBS at a concentration of 5×108 cells/ml, and 100 μl was subcutaneously injected into one flank of each mouse. Measurements were recorded every week, and changes in the average tumor volume were noted. After 7 weeks, at which time the average tumor volume reached 200 mm3 in each group, the mice were given intratumoral injections of 5 μg shNDRG1 or 5 μg shNC in 30 μl PBS every two days. Growth curves were plotted using average tumor volume of each experimental group at the set time points. The tumor size was measured with calipers in two directions, and the tumor volume (V) was calculated using the formula: V = (length × width)2 × 0.5.

Construction of the NDRG1 mammalian expression vector pcDNA3.1(+)/NDRG1 and the effect of transient transfection on cell proliferation and adhesion

The NDRG1 open reading frame was PCR amplified from OVCAR3 cells. The primer sequences used were: forward primer (NDRG1) 5′CGAAGCTTATGTCTCGGGAGATGCAG3′ and reverse primer 5′ATCTCGAGCTAGCAGGAGACCTCCAT3′. Real-time PCR was performed using the following parameters: 98°C for 30 sec, followed by 35 cycles of 98°C for 10 sec, 68°C for 30 sec and 72°C for 90 sec. The final primer extension at 72°C was performed for 10 min. The PCR product was then cloned into pcDNA3.1(+) (Invitrogen) using standard techniques. Either the obtained NDRG1 expression vector pcDNA3.1(+)/NDRG1 or empty vector pcDNA3.1(+) was transiently transfected into OVCAR3 cells using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. For the cell proliferation assay, cells were seeded into a 96-well plate (2×104 cells/well), and positive colonies were selected with G418 (Invitrogen) supplemented with growth medium. For the adhesion assay, wells of the 96-well culture plate were coated with Matrigel (BD Biosciences) at a concentration of 5 μg/well. Cells in medium containing 0.1% FBS were added to the wells (2×104/well) and incubated at 37°C for 2 h. After the unattached cells and medium were removed, normal medium with 10% FBS was added. The plate was then incubated at 37°C for an additional 12 h. The number of attached cells was reported as a percentage of total cells at the end of the incubation period. Each experiment was performed in triplicate wells and repeated three times.

Flow cytometry for cell proliferation

Cells were transfected with control or NDRG1 expression vectors. They were then trypsinized, centrifuged at 1,000 rpm, and resuspended in 0.5 ml PBS (1X). To fix the cells, 0.5 ml 100% cold ethanol was added to each sample and incubated for 20 min. After centrifugation at 1,000 rpm for 5 min, ethanol was decanted. According to the manufacturer’s instructions, the cells were incubated in the dark in 0.5 ml propidium iodide (PI) with RNase A for 30 min at 4°C. Results were analyzed by flow cytometry. Experiments were repeated three times.

Apoptosis assay

Annexin V-FITC apoptosis detection kit (Abcam) was used according to the manufacturer’s instructions. Approximately 5×105 cells were collected, washed twice with cold PBS, and resuspended in 500 μl of 1X binding buffer. Both 5 μl Annexin V-FITC and 5 μl PI were added, and samples were incubated in the dark at room temperature for 15 min. Apoptosis was evaluated by flow cytometry (LSR II; Becton-Dickinson, USA). The percentage of apoptotic cells was calculated using software FCS 3.0.

Statistical analysis

Statistical analysis was carried out using SPSS 16.0 for Windows. The two-tailed Student’s t-test was used for analyzing continuous variables. P<0.05 was considered to indicate a statistically significant result.


NDRG1 is expressed in the OC cell lines

We examined NDRG1 expression by quantitative real-time RT-PCR and western blot analysis in four well-established OC cell lines. NDRG1 mRNA and protein were expressed at relatively high levels in both the OVCAR3 and HO-8910 cells; they were significantly lower in the SKOV3 and A2780 cells (Fig. 1A). We selected OVCAR3 cells for subsequent knockdown experiments as this line expressed the highest levels of endogenous NDRG1 in the four cell lines examined.

Depletion of NDRG1 in OVCAR3 cells enhances proliferation

Three shRNA-NDRG1 expression vectors (shRNA1-NDRG1, shRNA2-NDRG1 and shRNA3-NDRG1) were transfected into OVCAR3 cells and the effects on biological processes were analyzed; transfection of an empty shRNA-NC vector served as a control. Depletion of NDRG1 at both the mRNA and protein levels was verified by both quantitative real-time RT-PCR and western blotting, respectively. NDRG1 expression was most significantly reduced by shRNA1-NDRG1 (Fig. 1B). Therefore, we chose to use shRNA1-NDRG1 for all subsequent experiments. We also generated a stable cell line (OVCAR3-shNDRG1) using this construct. Depletion of NDRG1 did not induce any observable morphological changes in the OVCAR3 cells (Fig. 1C).

OVCAR3-shNDRG1 cells displayed enhanced growth compared to OVCAR3-shNC cells at 72 h by MTT assay (P<0.05) (Fig. 1D). Consistent with this, OVCAR3-shNDRG1 cells formed more colonies than their OVCAR3-shNC counterparts (P<0.05) (Fig. 1E). These data indicate that NDRG1 plays a growth inhibitory role in OC.

Cell migration and invasion are enhanced following NDRG1 depletion

Previous studies have shown that NDRG1 likely plays a role in cancer metastasis (9,15). Here, we examined whether suppression of NDRG1 influences OVCAR3 cell migration and invasion. We performed wound healing assays to assess the effects on cell migration. Wound sizes in the OVCAR3-shNDRG1 cell group were significantly smaller than those in the OVCAR3-shNC group at both 24 and 48 h (P<0.05) (Fig. 2A). These data suggest that the NDRG1-depleted cells migrated faster than the control cells. These findings were complemented by data obtained from a Transwell assay. Significantly more OVCAR3-shNDRG1 cells migrated and invaded through the Transwell inserts compared to the OVCAR3-shNC control cells (P<0.05) (Fig. 2B and C). We also examined cell migration and invasion in another OC cell line, SKOV3. Similarly to what we found in OVCAR3 cells, NDRG1 knockdown in SKOV3 cells also resulted in enhanced migration and invasion (Fig. 2D). These data collectively indicate that suppression of NDRG1 promotes migration and invasion of OC cells in vitro.

Suppression of NDRG1 promotes tumor progression in a xenograft model

We next studied whether NDRG1 knockdown showed similar effects in vivo by using an OVCAR3 xenograft model in nude mice. Mice received intratumoral injections of OVCAR3-shNDRG1 (n=10) or OVCAR3-shNC (n=10) every two days. All mice in the OVCAR3-shNDRG1 group had significantly larger tumors than those in the OVCAR3-shNC group (P<0.05 from day 5 onwards; P<0.01 from day 13 onwards) (Fig. 3).

Overexpression of NDRG1 suppresses tumor cell proliferation and adhesion

Overexpression of NDRG1 in OVCAR3 cells significantly inhibited both cell proliferation (Fig. 4A and B) (P<0.05 at 48 h) and tumor cell adhesion (Fig. 4C) (P<0.05 at 48 h). We also induced NDRG1 overexpression in SKOV3 cells and found that this overexpression inhibited cell migration and invasion (Fig. 4D). These findings are consistent with our NDRG1 knockdown results. Taken together, the data showed that NDRG1 plays a growth suppressive and metastatic inhibitory role in OC.

Analysis of the cell cycle and apoptosis in NDRG1-overexpressing OVCAR3 cells

Cell cycle analysis showed that, compared to the control cells, NDRG1-overexpressing OVCAR3 cells displayed a significant increase in the percentage of cells in the G0/G1 phase (P<0.05), accompanied by a decrease in the percentage of cells in the S phase (P<0.05); there was no significant difference in the proportion of cells in the G2/M phase between the two groups (Fig. 5A).

Flow cytometry showed that apoptosis was increased in OVCAR3 cells transfected with pcDNA3.1(+)/NDRG1 when compared to control cells transfected with the empty vector (P<0.05) (Fig. 5B).

Overexpression of NDRG1 increases expression of p21 and p53

To assess downstream changes, we examined protein expression of NDRG1, p21 and p53 by western blotting following overexpression of NDRG1 in OVCAR3 cells. Both p21 and p53 were significantly increased in the pcDNA3.1(+)/NDRG1-transfected cells when compared to the control cells (P<0.01) (Fig. 6).


NDRG1 has been shown to play a role both in normal biological processes, such as cell differentiation (20) and disease pathogenesis, including hereditary motor and sensory neuropathy Lom (HMSNL) (21) and carcinogenesis (22). Importantly, functional studies in tumor cells have yielded conflicting results concerning the role of NDRG1 in modulating tumor growth and metastasis. Most current reports indicate that it functions as a tumor suppressor in a number of cancers, including breast (9), prostate (1012), pancreatic (7,8,13), cervical and endometrial cancer (14,23). However, in other types of tumors, for example, hepatocellular carcinoma, NDRG1 may actually have a growth-promoting role (17,18).

Knockdown of NDRG1 significantly enhanced cell proliferation, colony formation, migration, invasion and differentiation in most in vitro cell line studies. These include studies in pancreatic (8), cervical (24), prostate (11), lung (11), gastric (25) and colon cancer (15,26). Consistent with this, finding, overexpression of NDRG1 has been shown to inhibit proliferation, migration, invasion and differentiation (7,26,27).

In the present study, we used a combination of shRNA-mediated knockdown and overexpression to examine the function of NDRG1 in OC both in vitro and in vivo. We found that depletion of NDRG1 in OVCAR3 cells promoted xenograft growth in nude mice. These findings are in line with overexpression studies that found decreased xenograft growth when NDRG1 levels were increased (7,26,28). Additionally, we found that knockdown of NDRG1 significantly enhanced cell proliferation, colony formation, migration and invasion of OVCAR3 cells. Furthermore, overexpression of NDRG1 in OVCAR3 cells significantly inhibited their proliferation, adhesion and progression through cell cycle arrest and apoptosis. Our findings in OVCAR3 cells were supported by similar data obtained in SKOV3 cells (as presented in this study) as well as in HO8910-PM cells (14). Taken together, these data suggest that NDRG1 functions as a tumor suppressor in OC. However, its exact role in this disease clearly requires further investigation.

We also showed that p21 and p53 were induced following NDRG1 overexpression. These data suggest that p21 transcription may be increased in a p53- and NDRG1-dependent manner in OVCAR3 cells. Recent reports have shown that mutant p53 can retain the ability to transactivate p21 (29,30), which is in contrast to previous reports showing that only wild-type p53 induces p21 expression (31,32). Importantly, p21 expression does not necessarily reflect the status of p53 in these cells.

In conclusion, we showed that NDRG1 suppresses OC cell growth and migration. It may also suppress the metastasis of OC, and further clinical investigation of its role in human tumors is warranted.



American Cancer Society. Cancer Facts and Figures. Atlanta, GA: American Cancer Society; 2009, http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2009/indexurisimplehttp://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2009/index.


Mandić A, Tešić M, Vujkov T, Novta N and Rajović J: Ovarian cancer stage III/IV: poor prognostic factors. Arch Oncol. 9:13–16. 2001.


Li Z, Zhao X, Yang J and Wei Y: Proteomics profile changes in cisplatin-treated human ovarian cancer cell strain. Sci China C Life Sci. 48:648–657. 2005. View Article : Google Scholar : PubMed/NCBI


De Marco C, Rinaldo N, Bruni P, et al: Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma. PLoS One. 8:e553622013.PubMed/NCBI


Okuda T and Kondoh H: Identification of new genes Ndr2 and Ndr3 which are related to Ndr1/RTP/Drg1 but show distinct tissue specificity and response to N-myc. Biochem Biophys Res Commun. 266:208–215. 1999.


Zhou D, Salnikow K and Costa M: Cap43, a novel gene specifically induced by Ni2+ compounds. Cancer Res. 58:2182–2189. 1998.


Angst E, Dawson DW, Stroka D, et al: N-myc downstream regulated gene-1 expression correlates with reduced pancreatic cancer growth and increased apoptosis in vitro and in vivo. Surgery. 149:614–624. 2011. View Article : Google Scholar : PubMed/NCBI


Maruyama Y, Ono M, Kawahara A, et al: Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis. Cancer Res. 66:6233–6242. 2006. View Article : Google Scholar : PubMed/NCBI


Bandyopadhyay S, Pai SK, Hirota S, et al: Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression. Oncogene. 23:5675–5681. 2004. View Article : Google Scholar : PubMed/NCBI


Bandyopadhyay S, Pai SK, Gross SC, et al: The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res. 63:1731–1736. 2003.


Kovacevic Z, Sivagurunathan S, Mangs H, Chikhani S, Zhang D and Richardson DR: The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms. Carcinogenesis. 32:732–740. 2011. View Article : Google Scholar : PubMed/NCBI


Liu W, Iiizumi-Gairani M, Okuda H, et al: KAI1 gene is engaged in NDRG1 gene-mediated metastasis suppression through the ATF3-NFκB complex in human prostate cancer. J Biol Chem. 286:18949–18959. 2011. View Article : Google Scholar


Hosoi F, Izumi H, Kawahara A, et al: N-myc downstream regulated gene 1/Cap43 suppresses tumor growth and angiogenesis of pancreatic cancer through attenuation of inhibitor of κB kinase β expression. Cancer Res. 69:4983–4991. 2009.PubMed/NCBI


Zhao G, Chen J, Deng Y, et al: Identification of NDRG1-regulated genes associated with invasive potential in cervical and ovarian cancer cells. Biochem Biophys Res Commun. 408:154–159. 2011. View Article : Google Scholar : PubMed/NCBI


Li Q and Chen H: Transcriptional silencing of N-Myc downstream-regulated gene 1 (NDRG1) in metastatic colon cancer cell line SW620. Clin Exp Metastasis. 28:127–135. 2011. View Article : Google Scholar : PubMed/NCBI


Jiang K, Shen Z, Ye Y, Yang X and Wang S: A novel molecular marker for early detection and evaluating prognosis of gastric cancer: N-myc downstream regulated gene-1 (NDRG1). Scand J Gastroenterol. 45:898–908. 2010. View Article : Google Scholar : PubMed/NCBI


Yan X, Chua MS, Sun H and So S: N-Myc down-regulated gene 1 mediates proliferation, invasion, and apoptosis of hepatocellular carcinoma cells. Cancer Lett. 262:133–142. 2008. View Article : Google Scholar : PubMed/NCBI


Cheng J, Xie HY, Xu X, et al: NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinoma. Cancer Lett. 310:35–45. 2011. View Article : Google Scholar : PubMed/NCBI


Zou H, Wang D, Gan X, et al: Low TWEAK expression is correlated to the progression of squamous cervical carcinoma. Gynecol Oncol. 123:123–128. 2011. View Article : Google Scholar : PubMed/NCBI


Chen S, Han YH, Zheng Y, et al: NDRG1 contributes to retinoic acid-induced differentiation of leukemic cells. Leuk Res. 33:1108–1113. 2009. View Article : Google Scholar : PubMed/NCBI


Kalaydjieva L, Gresham D, Gooding R, et al: N-myc downstream-regulated gene 1 is mutated in hereditary motor and sensory neuropathy-Lom. Am J Hum Genet. 67:47–58. 2000. View Article : Google Scholar


Kovacevic Z and Richardson DR: The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis. 27:2355–2366. 2006. View Article : Google Scholar : PubMed/NCBI


Lv XH, Chen JW, Zhao G, et al: N-myc downstream-regulated gene 1/Cap43 may function as tumor suppressor in endometrial cancer. J Cancer Res Clin Oncol. 138:1703–1715. 2012. View Article : Google Scholar : PubMed/NCBI


Wang J, Cai J, Li Z, et al: Expression and biological function of N-myc down-regulated gene 1 in human cervical cancer. J Huazhong Univ Sci Technolog Med Sci. 30:771–776. 2010. View Article : Google Scholar : PubMed/NCBI


Liu YL, Bai WT, Luo W, et al: Downregulation of NDRG1 promotes invasion of human gastric cancer AGS cells through MMP-2. Tumour Biol. 32:99–105. 2011. View Article : Google Scholar : PubMed/NCBI


Fotovati A, Abu-Ali S, Kage M, Shirouzu K, Yamana H and Kuwano M: N-myc downstream-regulated gene 1 (NDRG1) a differentiation marker of human breast cancer. Pathol Oncol Res. 17:525–533. 2011. View Article : Google Scholar : PubMed/NCBI


Tsui KH, Chang YL, Feng TH, Chang PL and Juang HH: Glycoprotein transmembrane nmb: an androgen-downregulated gene attenuates cell invasion and tumorigenesis in prostate carcinoma cells. Prostate. 72:1431–1442. 2012. View Article : Google Scholar : PubMed/NCBI


Akiba J, Murakami Y, Noda M, et al: N-myc downstream regulated gene1/Cap43 overexpression suppresses tumor growth by hepatic cancer cells through cell cycle arrest at the G0/G1 phase. Cancer Lett. 310:25–34. 2011. View Article : Google Scholar : PubMed/NCBI


Gurova KV, Rokhlin OW, Budanov AV, et al: Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells. Cancer Res. 63:2905–2912. 2003.PubMed/NCBI


Campomenosi P, Monti P, Aprile A, et al: p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene. 20:3573–3579. 2001. View Article : Google Scholar : PubMed/NCBI


el-Deiry WS, Harper JW, O’Connor PM, et al: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54:1169–1174. 1994.


Elbendary AA, Cirisano FD, Evans AC Jr, et al: Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells. Clin Cancer Res. 2:1571–1575. 1996.PubMed/NCBI

Related Articles

Journal Cover

May 2014
Volume 31 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
Wang, B., Li, J., Ye, Z., Li, Z., & Wu, X. (2014). N-myc downstream regulated gene 1 acts as a tumor suppressor in ovarian cancer. Oncology Reports, 31, 2279-2285. https://doi.org/10.3892/or.2014.3072
Wang, B., Li, J., Ye, Z., Li, Z., Wu, X."N-myc downstream regulated gene 1 acts as a tumor suppressor in ovarian cancer". Oncology Reports 31.5 (2014): 2279-2285.
Wang, B., Li, J., Ye, Z., Li, Z., Wu, X."N-myc downstream regulated gene 1 acts as a tumor suppressor in ovarian cancer". Oncology Reports 31, no. 5 (2014): 2279-2285. https://doi.org/10.3892/or.2014.3072